Drug Combo Proves Powerful Against Lung Cancer Vestal NY

A two-drug combination treatment in Vestal proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Kent B LaMoureux
(607) 798-5230
169 Riverside Dr
Binghamton, NY
JONATHAN KLOSS, MD
(607) 798-5307
169 Riverside Drive
Binghamton, NY
ARUN SHETH, MD
(607) 798-5307
169 Riverside Drive
Binghamton, NY
Serazul Ali Khan, MD
607-763-6850
30 Harrison St Ste 100
Johnson City, NY
Stewart Allan Berkowitz, MD
607-687-6077
8 Halstead Ave
Owego, NY
Jonathan D Kloss
(607) 798-5307
169 Riverside Dr
Binghamton, NY
Shing Chin
(607) 798-5230
169 Riverside Dr
Binghamton, NY
MADHURI YALAMANCHILI, MD
(607) 798-5307
169 Riverside Drive
Binghamton, NY
RONALD HARRIS, DO
(607) 763-6850
30 Harrison Street
Johnson City, NY
Joseph Andrew Readling, MD
607-763-6850
30 Harrison St Ste 100
Johnson City, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Exercise for Prostate Cancer Vestal NY
Regular exercise may help protect men from prostate cancer, says a new study. U.S. researchers looked at 190 men who had a prostate biopsy and found that those who were moderately active -- anything equivalent to walking at a moderate pace for several hours a week -- were significantly less likely to be diagnosed with prostate cancer.
- Fungal Infection Treatments Vestal NY
- Exercise for Breast Cancer Survival Vestal NY
- Side Effect Of Chemotherapy Drugs Vestal NY
- Risks for Childhood Cancer Survivors Vestal NY
- Genetic Clues for Skin Cancer Therapies Vestal NY
- Hormone Therapy for Breast Cancer Vestal NY
- Delayed Prostate Cancer Therapy Vestal NY
- Hormone Therapy for Lung Cancer Vestal NY